Trials / Completed
CompletedNCT05835752
The Safety, Tolerability and Pharmacokinetic Study of RAY1225
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RAY1225
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAY1225 | Administered SC |
| DRUG | Placebo | Administered SC |
| DRUG | RAY1225 | Administered SC |
| DRUG | Placebo | Administered SC |
| DRUG | RAY1225 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2023-05-18
- Primary completion
- 2024-03-01
- Completion
- 2024-03-23
- First posted
- 2023-04-28
- Last updated
- 2026-03-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05835752. Inclusion in this directory is not an endorsement.